Inclisiran - Alnylam Pharmaceuticals

Drug Profile

Inclisiran - Alnylam Pharmaceuticals

Alternative Names: ALN-60212; ALN-PCSsc; PCSK9si

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; The Medicines Company
  • Class Amino sugars; Antihyperlipidaemics; Drug conjugates; Small interfering RNA
  • Mechanism of Action PCSK9 protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypercholesterolaemia

Most Recent Events

  • 06 Nov 2017 The Medicines Company plans the ORION-5 phase III trial for Hypercholesterolemia in Europe, the Middle East and North America before the end of 2017
  • 06 Nov 2017 The Medicines Company plans the phase III ORION-10 trial for hypercholesterolemia in North America before the end of 2017
  • 06 Nov 2017 The Medicines Company plans the phase III ORION-9 trial for hypercholesterolemia in North America, Europe, Israel and South Africa before the end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top